In this issue of Blood, Nair et al report on a computationally derived hepatocytespecific cis-regulatory module (HS-CRM8) to accomplish high tissue-specific expression in gene therapy for hemophilia. When HS-CRM8 is introduced upstream of a minimal liver-specific promoter in an adenoassociated virus (AAV) that expresses a codon-optimized hyperactive human factor IX (FIX) mutant (FIX Padua), it provides a >1 log increase in systemic FIX protein levels and supraphysiological activity over a range of vector doses. © 2014 by The American Society of Hematology.
CITATION STYLE
Markusic, D. M., & Herzog, R. W. (2014, May 15). A David promoter with Goliath strength. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2014-04-565507
Mendeley helps you to discover research relevant for your work.